Printer Friendly

Singaporean researchers develop molecular assay predicting treatment, survival in kidney cancer patients.

M2 PHARMA-August 4, 2014-Singaporean researchers develop molecular assay predicting treatment, survival in kidney cancer patients

(C)2014 M2 COMMUNICATIONS

4 August 2014 - Singaporean Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have jointly created the first molecular test kit able to predict treatment and survival outcomes in patients with kidney cancer, the parties said Friday.

The research was carried out retrospectively with tissue samples obtained from nearly 280 patients with clear cell renal cell carcinoma (ccRCC) who had surgery at SGH in 1999-2012. The test could classify patients into groups correlating to various survival and treatment outcomes. This is one of the first tests that is able to predict outcomes of anti-angiogenic treatment, a major goal for cancer care and industry, the researchers noted.

The assay has been validated at SGH and NCCS.

Findings for the test have been recently published in European Urology, the official journal of the European Association of Urology.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 4, 2014
Words:172
Previous Article:Dana-Farber Cancer Institute identifies new genetic markers linked to higher risk for pancreatic cancer.
Next Article:ZIOPHARM Oncology signs amendment and restatement of license and collaboration agreement with Solasia Pharma.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters